Stock Track | Tarsus Pharmaceuticals Soars 5.61% on Strong XDEMVY Sales Growth and Revenue Beat

Stock Track

Feb 24

Tarsus Pharmaceuticals, Inc. (TARS) saw its stock price soar 5.61% during Monday's intraday trading session, marking a significant upward movement for the biopharmaceutical company.

The surge appears to be driven by the company's strong fourth-quarter and full-year 2025 financial results, which were released post-market. Key highlights include full-year net product sales of XDEMVY reaching USD 451.4 million, representing growth of more than 150% year-over-year. Furthermore, the company's Q4 revenue of USD 151.668 million surpassed analyst estimates of USD 144.6 million. Tarsus also reiterated the peak sales potential for XDEMVY at over USD 2 billion and provided updates on clinical progress for other pipeline candidates, contributing to positive investor sentiment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1125320952"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1125320952\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1125320952?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 05:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125320952","market":"hk","top_or_hot":-1,"title":"Stock Track | Tarsus Pharmaceuticals Soars 5.61% on Strong XDEMVY Sales Growth and Revenue Beat","media":"Stock Track","content":"<p>Tarsus Pharmaceuticals, Inc. (TARS) saw its stock price soar 5.61% during Monday's intraday trading session, marking a significant upward movement for the biopharmaceutical company.</p><p>The surge appears to be driven by the company's strong fourth-quarter and full-year 2025 financial results, which were released post-market. Key highlights include full-year net product sales of XDEMVY reaching USD 451.4 million, representing growth of more than 150% year-over-year. Furthermore, the company's Q4 revenue of USD 151.668 million surpassed analyst estimates of USD 144.6 million. Tarsus also reiterated the peak sales potential for XDEMVY at over USD 2 billion and provided updates on clinical progress for other pipeline candidates, contributing to positive investor sentiment.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Tarsus Pharmaceuticals Soars 5.61% on Strong XDEMVY Sales Growth and Revenue Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Tarsus Pharmaceuticals Soars 5.61% on Strong XDEMVY Sales Growth and Revenue Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-24 05:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tarsus Pharmaceuticals, Inc. (TARS) saw its stock price soar 5.61% during Monday's intraday trading session, marking a significant upward movement for the biopharmaceutical company.</p><p>The surge appears to be driven by the company's strong fourth-quarter and full-year 2025 financial results, which were released post-market. Key highlights include full-year net product sales of XDEMVY reaching USD 451.4 million, representing growth of more than 150% year-over-year. Furthermore, the company's Q4 revenue of USD 151.668 million surpassed analyst estimates of USD 144.6 million. Tarsus also reiterated the peak sales potential for XDEMVY at over USD 2 billion and provided updates on clinical progress for other pipeline candidates, contributing to positive investor sentiment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TARS","symbol_name":"Tarsus Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1125320952","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125320952","pubTimestamp":1771880935,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Tarsus Pharmaceuticals, Inc. (TARS) saw its stock price soar 5.61% during Monday's intraday trading session, marking a significant upward movement for the biopharmaceutical company.The surge appears...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TARS":"Tarsus Pharmaceuticals, Inc."},"translate_title":"股票追踪|Tarsus Pharmaceuticals因XDEMVY强劲销售增长和收入增长而飙升5.61%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TARS":1},"content_text":"Tarsus Pharmaceuticals, Inc. (TARS) saw its stock price soar 5.61% during Monday's intraday trading session, marking a significant upward movement for the biopharmaceutical company.The surge appears to be driven by the company's strong fourth-quarter and full-year 2025 financial results, which were released post-market. Key highlights include full-year net product sales of XDEMVY reaching USD 451.4 million, representing growth of more than 150% year-over-year. Furthermore, the company's Q4 revenue of USD 151.668 million surpassed analyst estimates of USD 144.6 million. Tarsus also reiterated the peak sales potential for XDEMVY at over USD 2 billion and provided updates on clinical progress for other pipeline candidates, contributing to positive investor sentiment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}